Noncoding mutations in cancer genomes are frequent but challenging to interpret. PVT1 encodes an oncogenic lncRNA, but recurrent translocations and deletions in human cancers suggest alternative mechanisms. Here, we show that the PVT1 promoter has a tumor-suppressor function that is independent of PVT1 lncRNA. CRISPR interference of PVT1 promoter enhances breast cancer cell competition and growth in vivo. The promoters of the PVT1 and the MYC oncogenes, located 55 kb apart on chromosome 8q24, compete for engagement with four intragenic enhancers in the PVT1 locus, thereby allowing the PVT1 promoter to regulate pause release of MYC transcription. PVT1 undergoes developmentally regulated monoallelic expression, and the PVT1 promoter inhibits MYC expression only from the same chromosome via promoter competition. Cancer genome sequencing identifies recurrent mutations encompassing the human PVT1 promoter, and genome editing verified that PVT1 promoter mutation promotes cancer cell growth. These results highlight regulatory sequences of lncRNA genes as potential diseaseassociated DNA elements.
INTRODUCTION
The human genome encodes tens of thousands of long noncoding RNA (lncRNA) genes (Derrien et al., 2012) . While some lncRNAs have emerged as central regulators of transcriptional networks in development or disease (Fatica and Bozzoni, 2014; Schmitt and Chang, 2016) , the functions and regulation of most lncRNA genes are not known. Plasmacytoma variant translocation 1 (PVT1) was the first lncRNA gene identified in human cancer translocations as a recurrent breakpoint in Burkitt's lymphoma (Graham and Adams, 1986; Shtivelman et al., 1989) . Prior studies suggest PVT1-encoded lncRNA or microRNAs have oncogenic functions. The genomic region of 8q24 harboring PVT1 is one of the most frequently amplified regions in breast cancer (Curtis et al., 2012) . Indeed, PVT1 lncRNA has an oncogenic function itself by stabilizing the MYC protein (Tseng et al., 2014) . On the other hand, cancer genomes show recurrent structural rearrangements of PVT1 locus that disrupt PVT1 transcription, suggesting unknown regulatory functions of the PVT1 locus.
In mammalian cells, each chromosome is hierarchically organized into hundreds of megabase-sized topologically associated domains (TADs) (Dixon et al., 2012) . Cell-type-specific enhancer-promoter contacts take place within the TAD scaffold, leading to regulated gene expression (Pombo and Dillon, 2015) . Disruption of DNA boundary elements that separate neighborhoods of gene regulation recently has been recognized as an important cause of human diseases, including developmental malformations and cancer (Flavahan et al., 2016; Lupiá ñ ez et al., 2015) . Deletions, duplications, insertions, inversions, and translocations of genomic DNA, collectively termed ''structural variations,'' can alter the 3D conformation of the genome and cause pathogenic rewiring of enhancerpromoter contacts. The PVT1 locus harbors several intragenic enhancers that regulate transcription at target promoters by chromosome looping (Fulco et al., 2016; Zhang et al., 2016) . The role of PVT1 DNA regulatory elements in cancer is poorly understood at present. Engineered CRISPR with transcription factor domains, called ''CRISPR-interference'' (CRISPRi) or ''CRISPR-activation'' (CRISPRa), allows us to control gene expression at targeted promoters (Gilbert et al., 2013) . Functional screens employing engineered transcription factors targeting random sequences in the genome were pioneered 15 years ago (Blancafort et al., 2003; Park et al., 2003) , but expanding the technology to genome-wide screens for defined promoters has not been feasible until recently. Recent development of CRISPRi screening technologies has enabled systematic functional studies of regulatory DNA elements and lncRNA genes in the human genome (Gilbert et al., 2014; Liu et al., 2017) . We recently found that CRISPRi silencing of PVT1 unexpectedly enhanced cell proliferation in several cell types, including two breast cancer cell lines, glioblastoma cells, and induced pluripotent stem cells (Liu et al., 2017) .
Here, we show that a single DNA element in the PVT1 gene-the PVT1 promoter-is a tumor-suppressor DNA element that limits MYC oncogene expression. We further show that promoter competition in cis endows PVT1 promoter with the function of a DNA boundary element, blocking MYC oncogene from accessing cell-type-specific enhancers.
RESULTS

CRISPR Interference of PVT1 Enhances Proliferation and Cell Competition
We recently established genome-scale CRISPRi to interrogate the function of lncRNA loci (Liu et al., 2017) . We used single guide CRISPR RNAs (sgRNA) to direct a catalytically dead Cas9 (dCas9) protein fused to the KRAB repressor domain to the transcriptional start sites of lncRNA loci; each sgRNA can silence lncRNA expression in a targeted manner. The PVT1 locus encodes tens of annotated transcripts with at least six distinct transcriptional start sites (TSS1-6 from 5 0 to 3 0 ) (Figures 1A and S1A). The 5 0 TSS (TSS1) is located 53 kb downstream of the MYC gene, closely followed by TSS2 (+1.4 kb from TSS1). The other four TSS are scattered at $100-kb intervals throughout the >300 kb locus, with TSS3 (+ 96.3 kb), TSS4 (+194.2 kb), TSS5 (+194.7 kb), and TSS6 (+215.2 kb). Although PVT1 has been reported as an oncogenic lncRNA, we found that CRISPRi of the PVT1 locus surprisingly enhanced cell proliferation in multiple human cancer cell types (Liu et al., 2017) (Figure S1B ). We note that it is highly unusual to observe pro-growth effect in cancer cell lines, and the pro-growth effect of PVT1 sgRNAs was comparable to the largest effect on growth enhancement observed for silencing any protein coding gene (Gilbert et al., 2014) . Among the 60 sgRNAs targeting all 6 TSS, only CRISPRi of the 5 0 TSS1 or TSS2 of PVT1 increased cancer cell proliferation (Figure S1C) . CRISPRi of TSS1 was more potent than was TSS2, yielding results similar to those observed in both the MDA-MB-231 and the MCF-7 breast cancer cell lines ( Figure 1B) . 8 of 10 different sgRNAs targeting TSS1 enhanced cell proliferation, indicating a robust and reproducible effect (Figures S1C and S1D) . Therefore, we focus on TSS1 and hereafter refer to its flanking sequence as the ''PVT1 promoter. '' A critical element of tumor evolution is selection, wherein selectively advantageous mutations confer a fitness benefit to cells, resulting in their competitive outgrowth. In a heterogeneous population of cancer cells, individual clones grow at the expense of each other until one clone reaches dominance (Miller et al., 1988) . We designed a cell competition assay to investigate the effect of noncoding genes in a heterogeneous population ( Figure 1C) . Notably, cells with CRISPRi-PVT1 (mCherry+) outcompeted CRISPRi-LacZ control (GFP+) by drastically expanding up to 75% of the total cell population within 3 passages and reaching up to 85% within 10 passages. Control CRISPRi did not show any difference in growth rate with or without CRISPRi-PVT1 in the two breast cancer cell lines (Figures 1C and S2) . In 3D cell culture, CRISPRi-PVT1 cells generated both larger colonies and many more satellite colonies with stellate morphology than did control cells in the same well ( Figure 1D ), suggestive of an invasive phenotype (Kenny et al., 2007) . These results suggest cells with CRISPRi-PVT1 have the potential to become dominant in a heterogeneous tumor population. Moreover, CRISPRi-mediated silencing of PVT1 promoter enhanced breast tumor growth in subcutaneous xenografts in vivo, conferring a $40% increase in tumor growth rate compared to control xenografts harboring a non-targeting sgRNA (p = 2.1 3 10 À3 , paired two-tailed
Mann-Whitney U test) (Figures 1E and S1E) . Because silencing the PVT1 promoter enhances cancer cell proliferation, these results demonstrate that PVT1 promoter has an unexpected tumor-suppressor function.
CRISPRi-PVT1 Increases MYC Expression
To investigate how silencing of PVT1 promoter enhances cell proliferation, we conducted gene expression analysis via RNA sequencing (RNA-seq). CRISPRi-PVT1 by two independent sgRNAs effectively reduced the PVT1 lncRNA level as expected. See also Figures S1 and S2 and Table S1 .
Interestingly, both sgRNAs yielded MYC mRNA as the most prominently increased RNA in the entire transcriptome (Figure 2A) without induction of differential MYC promoter usage or isoform switch (Figures S3A and S3B) . MYC is a well-known oncogene requiring precise control; small quantitative gains in MYC expression can promote dramatic cell competition and proliferation (Kress et al., 2015) . For example, cells with three copies of the MYC gene grew at the expense of cells with two copies of MYC in the developing embryo (Clavería et al., 2013) . MYC overexpression is implicated in over 50% of human cancers, and the MYC gene is the adjacent chromosomal neighbor of PVT1 promoter, making MYC a plausible effector gene. We observed that CRISPRi-PVT1 also increased the MYC protein level by 2-to 3-fold, suggesting the MYC protein could contribute to the pro-growth phenotype ( Figure 2B ). Next, we systematically compared CRISPRi of 19 sgRNAs tiling across the PVT1 promoter (Figures S3C and S3D;  Table S1 ), and investigated each sgRNA's impact on steadystate PVT1 lncRNA and MYC mRNA levels. CRISPRi with sgRNAs targeting downstream of PVT1 TSS1 showed coordinately reduced PVT1 and increased MYC transcript levels, whereas sgRNAs targeting upstream of TSS1 did not alter expression of either PVT1 or MYC ( Figure 2C ). This result suggests that silencing PVT1 transcription is linked with increased MYC expression; the lack of an effect when targeting CRISPRi upstream of TSS1 also argues against potential divergent antisense transcripts from PVT1 promoter affecting MYC. The ability of CRISPRi-PVT1 to confer a competitive growth advantage was highly correlated with each sgRNA's potency to increase the MYC mRNA level (R = 0.752, Spearman's coefficient, p = 1.3 3 10 À4 ), more so than the level of PVT1 lncRNA silencing (R = 0.658 with p = 1.5 3 10 À3 ) ( Figure S3E ). A few CRISPRi results deviated from the overall inverse trend between PVT1 and MYC expression; thus elements beyond the core promoters also may be involved in this phenomenon. Furthermore, small interfering RNA (siRNA)-mediated knockdown of MYC mRNA reverted the proliferative advantage conferred by CRISPRi-PVT1 ( Figures 2D and 2E ), indicating that cell growth in PVT1-silenced cells requires increased MYC expression, similar to control cells ( Figure 2F ). Altogether, these results indicate MYC is a prominent effector of the progrowth phenotype induced by CRISPRi-PVT1. RNA (relative fold) . p values were calculated using an unpaired Mann-Whitney U test. (D and E) qRT-PCR for relative RNA levels of MYC and PVT1 (D) or relative cell counts at day 4 post-transfection (E) with siRNA targeting MYC with CRISPRicontrol or CRISPRi-PVT1 (R2). Error bars represent mean ± SEM (n = 3, biological replicates). (F) Correlation between relative cell counts and the MYC (left) or the PVT1 (right) RNA level described in Figures 2D and 2E. Spearman's coefficient (R) and p values are shown. *p < 0.05, using an unpaired t test compared with the control (dark gray). See also Figure S3 and Table S1 .
Uncoupling PVT1 Promoter versus PVT1 lncRNA in MYC Expression and Proliferation To understand how CRISPRi-PVT1 induces MYC transcription, we investigated the role of PVT1 lncRNA in MYC expression and the pro-growth phenotype. Three independent strategies showed that PVT1 lncRNA is dispensable for the tumor-suppressor function of PVT1 promoter. First, we positioned dCas9 to create a transcription block and truncated the PVT1 transcript without heterochromatin formation (Gilbert et al., 2013) . dCas9-mediated interference reduce full-length PVT1 lncRNA to the same level as dCas9-KRAB, but did not increase MYC expression or cell proliferation ( Figures 3A and S3D ). Second, we transfected antisense oligonucleotides (ASOs), which induce RNase H-mediated degradation of nuclear lncRNAs.
ASO-targeting PVT1 reduced PVT1 lncRNA levels, but failed to increase MYC expression or cell growth ( Figure 3B ). In fact, cell viability was reduced by ASOs targeting PVT1 lncRNA, consistent with the findings from a previous study (Tseng et al., 2014) . Third, siRNA-mediated knockdown through the RNA interference pathway again reduced PVT1 lncRNA levels without affecting MYC expression ( Figure 3C ). Altogether, these results suggest an lncRNA-independent mechanism by which the PVT1 promoter affects MYC expression and cell growth.
Promoter Competition Underlies Antagonism between PVT1 and MYC We identified a chromatin-based mechanism for PVT1 regulation of MYC transcription. The MYC gene is controlled by a multitude Control : 
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RNA (relative fold) Error bars indicate mean ± SEM (n = 3, biological replicates). *p < 0.05, using an unpaired t test compared with the control (dark gray). See also Figure S3 and Table S1 . of long-range cis-regulatory elements (Sotelo et al., 2010) . Chromatin immunoprecipitation sequencing (ChIP-seq) confirmed that the dCas9-KRAB protein specifically bound to the PVT1 promoter and induced histone H3 lysine 9 trimethylation (H3K9me3), a signature of KRAB-mediated gene repression (Liu et al., 2017) , at the PVT1 promoter, but not at MYC ( Figure S4 ). We used HiChIP, a method for protein-directed chromosome conformation, to target the enhancer-associated mark histone H3 lysine 27 acetylation (H3K27ac) to map the enhancer connectome in control and CRISPRi-PVT1 cells (Mumbach et al., 2016 (Mumbach et al., , 2017 . H3K27ac HiChIP revealed that the PVT1 promoter and MYC promoter, located 58 kb apart on the linear genome, exhibit high contact frequency in 3D within a small but dense TAD ( Figures  4A and S5A) . Notably, four intragenic enhancers within the PVT1 locus, herein named 822E, 866E, 912E, and 919E based on their genomic coordinates, normally preferentially contacted with the PVT1 promoter over the MYC locus in control cells. CRISPRi-PVT1 decreased contacts of these four enhancers with the PVT1 promoter but increased contacts with the MYC promoter and a MYC 3 0 -enhancer (Fulco et al., 2016) (Figures 4A and S5B) . Similar results demonstrating competitive interaction of PVT1 intragenic enhancer between PVT1 promoter and MYC 3 0 -enhancers were obtained in MCF-7 cells as measured by UMI-4C, an orthogonal method of targeted chromosome conformation capture with unique molecular identifiers (Schwartzman et al., 2016) (Figures 4B and S5C ). These results suggest that the PVT1 promoter acts as a boundary element in breast cancer cells: the PVT1 promoter interacts with the PVT1 intragenic enhancers and blocks the latter from inducing MYC expression.
MYC TSS
The PVT1 intragenic enhancers proved to be important for PVT1 promoter function. First, the four intragenic PVT1 DNA elements each demonstrate bona fide enhancer activity when cloned upstream of a minimal promoter in a luciferase reporter assay ( Figure S5D ). Second, CRISPRi of these enhancers in MDA-MB-231 cells lowered MYC and PVT1 mRNA levels, indicating that the endogenous PVT1 enhancers regulate both genes ( Figure 4C ). Third and importantly, we developed a dual CRISPRi strategy to assess the function of the PVT1 enhancers concomitant with PVT1 promoter silencing. Dual CRISPRi of PVT1 enhancers and PVT1 promoter showed that silencing of 3 of 4 PVT1 enhancers abrogated the increase in MYC mRNA level after PVT1 promoter silencing ( Figure 4C ). Enhancer 822E is particularly intriguing because it is required for MYC activation only upon PVT1 promoter silencing, but not in control cells. Together, this functional epistasis supports the idea that increased interaction between MYC and PVT1 enhancers is the basis of the induction of MYC transcription upon silencing of PVT1 promoter.
The model of promoter competition raises the hypothesis that PVT1 promoter specifically inhibits MYC promoter firing. In metazoan genomes, RNA polymerase II (Pol II) initiates transcription for 25-60 nucleotides in most genes and then pauses before release for productive elongation (Scruggs and Adelman, 2015) . The bromodomain protein BRD4 is a key regulator of pause release, both by controlling the phosphorylation state of the Pol II C-terminal domain and the interaction with enhancers (Devaiah et al., 2012) . MYC transcription is known to be highly sensitive to the bromodomain inhibitor JQ1 (Filippakopoulos et al., 2010) , and we found that JQ1 treatment similarly reduced PVT1 transcript level, suggesting that both MYC and PVT1 are regulated by bromodomain proteins ( Figure S5E ). Moreover, we found that CRISPRi-PVT1 decreased BRD4 occupancy at PVT1 promoter, but significantly increased BRD4 occupancy at the MYC promoter as shown by ChIP-qPCR ( Figure 4D ). CRISPRi-PVT1 decreased Pol II initiation at the PVT1 locus but did not alter pol II initiation at MYC, as shown by serine 5-phosphorylated polymerase (Pol II-S5P) occupancy ( Figure 4E ). In contrast, CRISPRi-PVT1 decreased elongating serine 2-phoshorylated RNA polymerase (Pol II-S2P) at PVT1 but increased polymerase elongation for MYC ( Figure 4F ). Moreover, interrogation of nascent transcription by 4-thiouridine (4sU) labeling (Cleary et al., 2005) showed that PVT1 silencing decreased nascent PVT1 transcript levels but nearly doubled MYC mRNA synthesis ( Figure 4G ). These results suggest that the PVT1 promoter is a brake for MYC gene transcriptional elongation.
The model of PVT1-MYC promoter competition also potentially explains the cell-type specificity of PVT1's function. CRISPRi-PVT1 did not induce MYC transcription in some cell types, such HCT116 colon cancer cells or HeLa cervical carcinoma cells. (Figure S5F ). We found that in these cell types, MYC loops to the CCAT1 enhancer instead of PVT1 ( Figures  S5G-S5J) ; the colon cancer result is consistent with a prior study (Xiang et al., 2014) . These observations provide additional evidence that the chromosome conformation landscape is an important determinant of the dynamic interplay between PVT1 and MYC.
PVT1 Promoter Reversibly Regulates MYC Transcription Conversely, enforced transcription from PVT1 promoter inhibited MYC transcriptional elongation. We engineered MDA-MB-231 cells to stably express dCas9 fused to potent transcription chromosome interaction induced by CRISRPi-PVT1. Shaded region indicates mean ± SEM (n = 2, biological replicates). p values of each interaction between MYC 3 0 -enhancer and PVT1 intragenic enhancer were calculated using Fisher's exact test. See also Figure S4 and S5 and Table S1 .
activation domains (dCas9-VP64) (Konermann et al., 2015) ; expression of specific sgRNAs allowed us to activate transcription of endogenous loci ( Figure 5A ). CRISPR activation (CRISPRa)
of PVT1 increased PVT1 lncRNA but significantly decreased MYC mRNA level ( Figure 5B ). Moreover, CRISPRa of PVT1 reduced BRD4 occupancy at MYC promoter, reduced Pol II elongation 
CRISPRa :
CRISPRa : Error bars represent mean ± SEM (n = 3, biological replicates). *p < 0.05, using an unpaired t test compared with the control (gray). ns, not significant (p > 0.05); nd, not detected. See also Figure S5 and Table S1 . 
(legend continued on next page)
at MYC, and reduced MYC nascent transcript ( Figures 5C-5F ). These effects were highly specific as Pol II initiation at MYC was not affected. Moreover, CRISPRi-MYC promoter increased PVT1 transcription ( Figure 5G ). These results further distinguish the RNA products as separable from the DNA element competition of the two promoters. Altogether, these results support a model of bidirectional regulation of PVT1 and MYC genes via promoter competition ( Figure 5H ).
Monoallelic Regulation of PVT1 Promoter Controls MYC Expression in cis
A strong prediction arising from the promoter competition model is that the PVT1 promoter should regulate the MYC promoter on the same chromosome (i.e., the allele in cis). PVT1 lncRNA is known to diffuse throughout the nucleus and cytoplasm. The previously published models of PVT1 lncRNA exerting oncogenic function by interaction with RNA binding proteins or other regulatory RNAs throughout the cell predict an effect on both homologous chromosomes (i.e., action in trans) (Tseng et al., 2014; Wang et al., 2014a; Xu et al., 2017b) . We and others recently described the recognition of widespread random monoallelic chromatin accessibility wherein one of two alleles in a diploid cell is active in a heritable fashion (Xu et al., 2017a) . Using cells derived from an F1 hybrid mouse of two highly divergent parental genome, 129S1 (here referred to as 129) and Castaneous (Cast), we isolated individual cell clones and measured chromatin accessibility, histone modifications, and RNA transcripts in an allele-specific fashion ( Figure 6A ). In the mouse embryonic stem cells (mESC), Pvt1 showed bi-allelic transcription and no difference in chromatin status between two alleles. After differentiation into the neural precursor cells (mNPC), however, some clones showed monoallelic transcription of Pvt1 ( Figure 6B ). A histone mark for active promoters, histone H3 lysine 4 trimethylation (H3K4me3), was observed only on the transcribed allele, whereas heterochromatic H3K9me3 was only present on the silent allele at Pvt1 promoter. Importantly, monoallelic Pvt1 promoter activation led to the specific reduction of Myc chromatin accessibility and mRNA level from the same chromosome, but not of the homologous chromosome in trans in the same nucleus ( Figure 6B ).
We found mono-or bi-allelic transcription of Pvt1 is associated with a reduction of Myc transcription in cis across numerous independent mNPC clones ( Figure 6C ). Based on SNPs from each allele, we calculated the allele bias of histone marks, chromatin accessibility, or RNA transcription from 11 clones, represented by d-score. A positive or negative d-score indicates allelic bias toward 129 or Cast allele, respectively ( Figure 6A ). As expected, the d-score of chromatin accessibility at Pvt1 promoter is highly correlated with the d-score of Pvt1 lncRNA level (R = 0.990, Spearman's coefficient, p = 9.0 3 10 À11 ) ( Figure S6A ).
Importantly, the d-score of Pvt1 promoter chromatin accessibility is inversely correlated with the d-score of Myc mRNA level (R = À0.724 with p = 2.3 3 10 À3 ) ( Figure 6D ). Indeed, the ) ( Figure S6B ). We expanded this analysis with additional independent clones via targeted reverse transcription followed by amplicon sequencing ( Figure S6C ). From 35 mNPC clones, the d-scores of Pvt1 and Myc transcript levels are inversely correlated (R < À0.427 with p < 1.0 3 10 À2 ), whereas the control gene (Tbp) showed no correlation with Pvt1 ( Figures 6E and S6D) . Altogether, these results indicate that the PVT1 promoter directly represses MYC transcription in cis, consistent with a DNA-element-based mechanism.
Recurrent Mutations Encompassing the PVT1 Promoter in Cancer Patients
Finally, somatic mutations in human cancers support a tumorsuppressive role of the PVT1 promoter. The DNA sequence of the PVT1 promoter, especially between TSS1 and TSS2, exhibits a higher degree of evolutionary conservation than does other portions of the PVT1 lncRNA, and noncoding variations in this region are predicted to be especially damaging (Figures 7A and S7A) . We analyzed published cancer genomes from a variety of human tumors, and annotated the frequency of somatic mutations in the PVT1 promoter versus mutations in other annotated lncRNA promoters on human chromosome 8 (chr8). PVT1 promoter exhibited recurrent point mutations and indels in human breast cancer and malignant lymphoma, but not other cancer types ( Figure S7B ). The 8q24 region spanning MYC and PVT1 was recently reported to be a hotspot for somatic structural variants (SVs) in breast cancer (Nik-Zainal et al., 2016) . Further analysis of these data indicates that the PVT1 promoter region is significantly enriched for SVs as compared to other lncRNA promoters ( Figure 7B ) (p value = 1 3 10 À5 , false discovery rate [FDR] < 0.03). Human breast tumors exhibited diverse SVs, including deletions, inversions, and duplications, that overlapped the PVT1 promoter ( Figure 7C ) and are expected to inactivate the tumor-suppressive function of the PVT1 promoter. We also identified rare but illustrative intra-chromosomal inversion in an estrogen receptor negative (ERÀ) HER2+ human breast tumor that breaks precisely at intron 1 of PVT1, separating the PVT1 promoter from intragenic enhancers and creating a PVT1 fusion transcript with genes located more than 40 Mb away ( Figures 7D and S7C ). Chromosomal inversion and the PVT1 fusion transcripts are supported by both DNA and RNAseq and are present in the majority of tumor cells, suggesting that this event occurred early or was strongly selected. PVT1 translocations with at least 15 different fusion partners have been reported in diverse types of human cancers; these translocations invariably occur in intron 1 of PVT1 gene, separating the PVT1 promoter from its genomic context (Chinen et al., 2014; Kim et al., 2014a; Nagoshi et al., 2012; Northcott et al., 2012; Pleasance et al., 2010; Shtivelman et al., 1989) (Table S2 ). These diverse translocations share the property of altering the chromatin and TAD environment of PVT1 promoter, (D) Correlation between the d-score for accessibility of the PVT1 locus from ATAC-seq and MYC transcription level from RNA-seq. For (C) and ( See also Figure S6 and Table S1 . suggesting inactivation of repressive function of PVT1 promoter as a unifying mechanism.
To demonstrate that mutations in the PVT1 promoter are sufficient to promote cell proliferation, we used CRISPR-mediated genome editing to mutate the PVT1 promoter. After genome editing, we passaged the edited and unedited cells as a pool in a competitive growth assay. Indeed, alleles with small deletions at the PVT1 promoter were significantly enriched up to 3-fold after ten passages, indicating that PVT1 mutations confer a distinct growth advantage (p < 0.01 for each allele) ( Figure 7E ). Mutant alleles of the PVT1 promoter were further enriched longitudinally over 30 passages, suggesting their effects persist and dominate over time ( Figure S7D ). Further, we generated clonal MDA-MD-231 cells harboring small deletions at PVT1-TSS. 5 out of 6 clones showed increased MYC mRNA level up to 1.5-fold over cells harboring wild-type PVT1 promoter ( Figures 7F and S7E ). These experimental results corroborate the findings from human cancer genomes and suggest that the PVT1 promoter is a candidate tumor-suppressor DNA element.
DISCUSSION
Our studies may shed light on a long-standing puzzle in cancer genetics. PVT1 was the first lncRNA gene associated with cancer and likely also the first lncRNA associated with human disease. Frequent translocations, retroviral insertions, and interstitial deletions that disrupt the PVT1 transcription unit have been known for more than 25 years (Shtivelman et al., 1989) . In 1990, Shtivelman and Bishop (1990) hypothesized that PVT1 translocations activate MYC transcription, but the potential mechanism has remained obscure. Our results suggest that the PVT1 locus harbors a series of DNA regulatory elements for MYC, and activity of the PVT1 promoter gates the ability of MYC to access these PVT1 intragenic enhancers. Hence, the PVT1 promoter is a tumor-suppressor DNA element. Silencing the PVT1 promoter increases MYC transcription and cell proliferation in a manner independent of PVT1 lncRNA. Developmental monoallelic regulation of PVT1 may also regulate somatic stem cell competition, a possibility that will be addressed elsewhere. The topography of the MYC-PVT1 interval may underlie the tissue specificity of PVT1 promoter action. PVT1 promoter is located 3 0 of MYC and regulates downstream enhancers of MYC, such as those active in breast cancer cells. In contrast, in HeLa and HCT116 cells, where PVT1 promoter does not regulate MYC, upstream MYC enhancers, such as the multicopy insertion of human papillomavirus sequence 500 kb upstream of MYC in HeLa (Adey et al., 2013) or coloncancer-specific enhancer 300 kb upstream of MYC in HCT116 cells (Sur et al., 2012) , are dominant.
A prior study using chromosome engineering in mice suggested that PVT1 lncRNA acts as an oncogene through posttranslational regulation of MYC protein (Tseng et al., 2014) . In fact, our model is fully compatible with and may better explain the prior results. First, Tseng et al. (2014) engineered different tandem duplications of the MYC-PVT1 interval and found that the MYC-PVT1 genomic DNA needs to be co-amplified in cis to promote breast tumor growth in vivo. Amplification of either MYC or PVT1 alone had no detectable tumorigenic activity. The cis requirement is readily explained by regulated enhancerpromoter contact in the same TAD, but is difficult to explain for trans-acting lncRNA and protein products. Second, to evaluate the requirement of PVT1 lncRNA, Tseng et al. (2014) generated a $300-kb deletion of the PVT1 locus that also removed all four PVT1 intragenic enhancers. This PVT1 deletion lowered MYC level and abrogated tumorigenic activity in vivo, exactly as our model would predict. The recognition of the PVT1 promoter as a MYC transcriptional repressor suggests that PVT1 maintains rheostatic control of MYC expression. The PVT1 promoter, as a DNA element, limits MYC transcription, whereas the PVT1 RNA product sustains the MYC protein level. These two strategies of control are expected to constrain MYC protein levels within a narrow range. The function of the PVT1 promoter is likely dominant over that of PVT1 lncRNA as evidenced by our experimental data and the pattern of human cancer mutations. PVT1 joins other lncRNA loci as dual DNA and RNA regulatory elements with opposing functions, such as Haunt and linc-p21 (Groff et al., 2016; Yin et al., 2015) . Although we have shown that inactivation of the PVT1 promoter enhances cell proliferation in established cancer cells, it remains to be seen whether a PVT1 promoter mutation alone can cause cancer in vivo.
Our study suggests the lncRNA gene promoter as a new class of DNA boundary elements that ensure proper allocation of enhancer-promoter interactions. We posit that lncRNA promoters (and indeed any gene promoter) may serve this function because of (1) their participation in long-range 3D chromatin interactions and (2) promoter-promoter competition to engage the same set of enhancers. MYC and PVT1 transcription units do not overlap and are separated by 55 kb; hence, 3D chromosome conformation is essential for promoter competition to take place. Promoter competition differs from currently known mechanisms of lncRNA-based regulation in cis, where transcription through the target DNA element mediates the effect (Anderson et al., 2016; Csorba et al., 2014) . We show that when promoter competition is abrogated by silencing or mutation of the PVT1 promoter, pathogenic rewiring of enhancer-promoter contact See also Figure S7 and Tables S1 and S2. occurs between intragenic PVT1 enhancers and the MYC promoter, resulting in increased MYC expression. lncRNA promoters are more evolutionarily conserved than their gene bodies (Derrien et al., 2012) , and hence this mechanism could be general. Transcriptome analyses of targeted mutations (Engreitz et al., 2016) Figure S7F ). The advent of powerful technologies to edit the genome, epigenome, and map enhancer connectomes now permits systematic testing of these concepts. We note that even from a DNA-centric viewpoint, the lncRNA transcript is hardly an irrelevant molecule, but is the evidence of successful competition of the lncRNA promoter at the expense of target gene promoters. With the precise mapping of tens of thousands of precise lncRNA promoters in the human genome (Hon et al., 2017) , future investigations using strategies reported herein will likely illuminate novel function of lncRNA loci in cancer and other disease states.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines MDA-MB-231, MCF-7, HEK293, HEK293T and HeLa cells were maintained with DMEM (Thermo Fisher, Cat#11995) supplemented with 10% fetal bovine serum (GE Healthcare, Cat#SH30396.03) and 1% pen-strep (Thermo Fisher, Cat#15140). SKBR3 and HCT116 cells were maintained with modified McCoy's 5A (Thermo Fisher, Cat#16600) supplemented with 10% fetal bovine serum and 1% pen-strep. MCF-10A cells were maintained with DMEM:F12(1:1) (Thermo Fisher, Cat#11320) supplemented with 5% horse serum (Thermo Fisher, Cat#16050122), 10 mg/ml insulin (Sigma Aldrich, Cat#I0516), 20 ng/ml epidermal growth factor (Thermo Fisher, Cat#PHG0311), 100 ng/ml cholera toxin (Sigma Aldrich, Cat#C8052), 0.5 mg/ml hydrocortisone (Sigma Aldrich, Cat#H0888) and 1% pen-strep. mESCs were cultured in serum (Fisher Scientific, SH30071.03) and LIF-containing (EMD Millipore, Cat#ESG1107) media on 0.2% gelatin-coated plates. mNPC cells were maintained on plates which were coated with 0.2% gelatin with N2B27 media which is composed of 1:1 mixed media of DMEM:F12(1:1) and Neurobasal media (Thermo Fisher, Cat#21103049) supplemented with 1 3 NDiff Neuro2 Medium Supplement (EMD Millipore, Cat#SCM012), 0.5 3 B-27 Supplement (Thermo Fisher, Cat#17504044), 1 3 Glutamax Supplement (Thermo Fisher, Cat#35050061), 0.1 mM of b-mercaptoethanol (Thermo Fisher, Cat#31350010), 10 ng/ml of epidermal growth factor (EGF, Peprotech, Cat#31509) and 10 ng/ml of fibroblast growth factor-basic (FGF, Peprotech, Cat#100-18B). In order to differentiate into mNPCs from mESC, mESCs were plated on gelatin-coated plates in N2B27 media for 7 days. On day 7, cells were dissociated with Accutase and cultured in suspension in N2B27 media supplemented with 10 ng/ml of FGF and 10 ng/ml of EGF. On day 10 cells embryoid bodies were plated onto 0.2% gelatin-coated plates and allowed to grow for 3 passages before sub-cloning single cells. For routine sub-culture, 0.25% Trypsin-EDTA (Thermo Fisher, Cat25200-114) were used for detaching of most cell lines; TrypLE Express Enzyme (Thermo Fisher, Cat#12604039) for MCF-10A or Accutase (EMD Millipore, Cat#SCR005) for mNPC. Puromycin (Thermo Fisher, Cat#A11138) was used at final concentration 1 mg/ml for all cell lines except SKBR3 (final 0.5 mg/ml) for 2 to 4 days. Blasticidin (Thermo Fisher, Cat#A1113903) was used at 4 mg/ml for MDA-MB-231, MCF-7, MCF-10A or HeLa, 2 mg/ml for HEK293 or SKBR3, or 16 mg/ml for HCT116 for 8 days. Hygromycin (Thermo Fisher, Cat#10687010) was used at 200 mg/ml for MDA-MB-231 for 8 days. All human cell lines were obtained from ATCC (American Type Culture Collection) and were tested for mycoplasma contamination.
Mouse subcutaneous xenograft All animal experimentation was conducted according to protocols approved by the Stanford University Institutional Animal Care and Use Committee (IACUC). Six-week old female NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ mice (Jackson laboratories) were housed at the animal care facility at Stanford University School of Medicine, kept under standard temperature, humidity, and timed lighting conditions and were provided with mouse chow and water ad libitum. For imaging, MDA-MB-231 cells expressing dCas9-KRAB were infected with lentivirus harboring EF1a-luciferase-2A-Hygro cassette. After hygromycin selection, luciferase activity was validated using Luciferase Reporter Assay System (Promega, Cat#E1500). Non-targeting sgRNA or sgRNA targeting PVT1 (R2) was transduced by lentivirus infection followed by puromycin selection for 4 days. Luciferase-labeled MDA-MB-231 cell line expressing dCas9-KRAB with non-targeting sgRNA or sgRNA targeting PVT1 was injected subcutaneously and bilaterally on the flank of the mice in 0.1 mL of sterile PBS (3 3 10 6 cells/animal) mixed with 50% Matrigel (BD Biosciences, Cat#356231). For bioluminescence imaging, mice received luciferin (150 mg/kg, 10 min prior to imaging) and were anesthetized and imaged in an IVIS 100 imaging system (Perkin Elmer). Images were analyzed with Living Image software (Perkin Elmer). Bioluminescent flux (photons/sec/cm 2 /sr) was measured for the primary tumors for up to 6 weeks. J.K. performed cell injection, animal maintenance, imaging, and quantification and was blinded for the animal experiments.
METHOD DETAILS Lentivirus production and infection
For virus production, 5 3 10 6 or 1 3 10 7 of HEK293T cells were plated per 10 cm or 15 cm plate, respectively. The following day, plasmid encoding lentivirus was co-transfected with pMD2.G and psPAX2 into the cells using Lipofectamine 3000 (Thermo Fisher. Cat#L3000) or TransIT LT1 (Mirus, Cat#MIR2300) according to the manufacturer's instructions. Supernatant containing viral particles was collected 48 hr after transfection and filtered. For lentivirus encoding individual sgRNAs, virus was concentrated using Lenti-X concentrator (Clontech, Cat#631232) and stored at À80
C. Viral titer was verified by adding 10 ml to 640 ml of supernatant containing virus (1/10 for 10-fold concentrated virus) to the cells. For virus infection, virus, and polybrene (final 4 mg/ml, Sigma Aldrich, Cat#107689) was added to 25% confluent cells. Fresh media was added 24 hr after infection. Media was changed with media containing appropriate antibiotics 48 hr after infection. After drug selection, cells were maintained for at least one day without drug for further experiments.
CRISPR construct pHR-SFFV-dCas9-BFP (Addgene, Cat#46910) and pHR-SFFV-dCas9-BFP-KRAB (Addgene, Cat#46911) were used for making clonal MDA-MB-231 or MCF-7 cell lines expressing dCas9 or dCas9-KRAB. For multiple cell line experiments, dCas9-BFP-KRAB-2A-Blast construct was used which was generated by inserting 2A-Blast cassette into dCas9-BFP-KRAB vector. sgRNAs were cloned into mU6(modified)-sgRNA-Puromycin-mCherry vector, which was modified from Addgene-Cat#46914. For competitive cell growth assay, mCherry ORF was replaced with EGFP. For CRISPR-mediated gene activation experiments, dCas9-VP64-2A-Blast (Addgene, Cat#61425) and MS2-P65-HSF1-Hygro (Addgene, Cat#61426) vectors were used and sgRNA was inserted into sgRNA2.0-puro-mCherry vector which was modified from Addgene-Cat#61427. For purifying recombinant Cas9 protein, pET28-Cas9 expression vector was generated from p3s-Cas9 (Addgene, Cat#43935). sgRNA sequences not included in CRiNCL library (Liu et al., 2017) were chosen considering number of their potential off-target sites (Cho et al., 2014) . All sgRNAs used in this study are listed in Table S1 .
Cell growth assay 3 3 10 3 cells or 1 3 10 5 cells were plated per 96-well or 12-well plates. For MTT assay, MTT labeling reagent (Roche, Cat#11465007001) was added and incubated at 37 C for 4 hr. Then solubilization solution was added and incubated at 37 C for overnight. Cell proliferation was measured by using spectrometer (Molecular Devices) as A550nm-A690nm. The absorbance at day 4 post plating was to the signal at day 1 post plating. For MTT assay, mean was averaged from two technical replicates. For cell counting, cells were detached 4 days post plating and counted by using Countess II FL (Thermo Fisher) with Trypan blue staining. Mean counts from triplicate measurements were used to calculate cell growth rate.
siRNA or ASO One day before transfection, 2 3 10 5 cells were plated on a 12-well plate. siRNA (QIAGEN) or ASO (Exiqon) was transfected into the cells using DharmaFECT4 (Dharmacon, Cat#T-2004) or Lipofectamin 2000 (Thermo Fisher, Cat#11668), respectively, with final 50 nM in 1 mL media. Media was refreshed 24 hr post transfection and cells were harvested or sub-cultured 48 hr post transfection. siRNA or ASO sequences are listed in Table S1 .
qRT-PCR RNA was prepared using RNeasy Plus mini Kit (QIAGEN, Cat#74136). Purified RNA was quantified by Nanodrop (Thermo Fisher). For qRT-PCR, 60 ng of RNA and Brilliant qRT-PCR mastermix (Agilent, Cat#600825) were used. Each Ct value was measured using Lightcycler 480 (Roche) and each mean dCt was averaged from triplicate qRT-PCR reaction. Relative RNA level was calculated by ddCt method compared to GAPDH control. The mean dCt value of each replicate was used to calculate p value. Primer sequences are listed in Table S1 .
RNA-seq 50 ng of total RNA was used to RNA-seq. RNA-seq libraries were prepared using Truseq Stranded total RNA LT kit (Illumina, Cat#RS-122-2201) as according to manufacturer's instructions. Paired-end reads were obtained on HiSeq 4000. Reads were mapped by using Tophat2 (Kim et al., 2013) and analyzed by using DESeq2 (Love et al., 2014) .
Western blotting
After puromycin selection, cells were harvested and lysed using RIPA buffer (50 mM Tris pH 8.0, 1mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.1% sodium doxycholate) supplemented with cOmplete proteinase inhibitor cocktail (Roche, Cat# 11697498001). Lysate was homogenized using sonication and quantified using BCA reaction (Thermo Fisher, Cat#23227). 20 mg of lysate was resolved on NuPAGE 4%-12% Bis-Tris gel (Thermo Fisher, Cat# NP0322) and transferred to nitrocellulose membrane (GE Healthcare, Cat#10600002). After blocking using Odyssey blocking buffer-PBS (LI-COR BioSciences, Cat#927-40003), membrane was incubated for overnight at 4 C with antibody against to MYC (Cell Signaling, Cat#5605S, 1/1,000) or GAPDH (Santa Cruz, Cat#sc69778, 1/5,000). Afterward, the membrane was incubated for 1 hr at room temperature with IRDye 800CW goat antirabbit secondary antibody (LI-COR BioSciences, Cat#926-32211, 1/10,000) and IRDye 680RD goat anti-mouse secondary antiboby (LI-COR BioSciences, Cat#926-68070, 1/10,000). Protein bands were visualized and quantified using Odyssey CLx and Image Studio 1.0.11 (LI-COA BioSciences).
Cell growth competition assay
Cells with CRISPRi-Control or CRISPRi-PVT1 were marked with different fluorescent proteins encoded in lentiviral vector and then co-cultured. Following puromycin selection for lentivirus infection with sgRNA, cells were counted and mixed GFP+ cells (for control sgRNA) and mCherry+ cells (for control sgRNA or sgRNA-PVT1). For 2D-culture, 1 3 10 5 cells were plated on 12-well plate and maintained by routine sub-culture every other day at 1:4 ratio and analyzed by FACSAria II (BD Biosciences). For 3D-culture, 2.5 3 10 5 cells in 2.5 mL of media containing 2% Matrigel were plated on 6-well plate which was coated with 450 mL of Matrigel. Media containing 2% Matrigel was refreshed at every 4 days. Fluorescence microscope images were taken by 5 3 magnification of Axiovert 200M (Carl Zeiss).
Northern blotting 10 mg of RNA was dissolved on a denaturing 1.2% MOPS agarose gel using formaldehyde load dye (Thermo Fisher, Cat#AM8550) followed by transferring to BrigtStar-Plus nylon membrane (Thermo Fisher, Cat#AM10104) using NorthernMax Transfer Buffer (Themo Fisher, Cat#AM8672) for overnight. RNA transferred to membrane was crosslinked by UV Stratalinker 2400 (Stratagene) with autocrosslink protocol and baked at 80 C for 30 min. Membrane was incubated in ULTRAhyb-Oligo buffer (Thermo Fisher, Cat#AM8663) for 1 hr at 42 C. Then, membrane and 500 ng of denatured probe was incubated with ULTRAhyb-Oligo buffer for overnight at 55 C. After hybridization, membrane was washed twice with NorthernMax Low-Stringency Wash Solution (Thermo Fisher, Cat#AM8673) for 5 min followed by washed twice NorthernMax High-Stringency Wash Solution for 15 min at 42 C (Thermo Fisher, Cat#AM8674). Membrane was blocked using Odyssey Blocking Buffer-PBS containing 1% SDS for 1 hr at room temperature. Then, membrane was incubated with Streptavidin-IRDye 800CW (LI-COR BioSciences, Cat#926-32230, 1/10,000) in Odyssey Blocking Buffer-PBS containing 1% SDS for 30 min at room temperature followed by wash three times using PBS containing 0.1% Tween-20 for 5 min. RNA bands were visualized and quantified using Odyssey CLx and Image Studio 1.0.11.
Templates of probes were amplified using reverse-transcriptase and purified on agarose gel. Then, biotin incorporated probe was generated by PCR using Hot Start Taq DNA polymerase (NEB, Cat#M0495L) and standard Taq reaction buffer (NEB, Cat#B9014S) supplemented with 125 mM of dTTP, 125 mM of biotin-16-dUTP (Roche, Cat#11093070910) and 250 mM of each dATP, dCTP and dGTP (NEB, Cat#N0446S). Probe DNA was dissolved on an 1.2% agarose gel to confirm of appropriate incorporation of biotin and purified by gel extraction. Probes were denatured prior to hybridize by incubation for 10 min at 95 C. Primer sequences used to make probes are listed in Table S1 .
ATAC-seq
For ATAC-seq, 5 3 10 4 cells were harvested and washed by PBS. Cells were resuspended in lysis buffer (10 mM Tris-HCl pH 7.5, 10 mM NaCl 2 , 3 mM MgCl 2 , 0.05% NP40) and pelleted. Cell pellet was resuspended in TD buffer (10 mM Tris-HCl pH 7.5, 10 mM MgCl 2 , 10% dimethlyformamide). 2.5 ml of Tn5 (Illumina, Cat#Fc-121-1030) was added to permeabilized cells and incubated at 37 C for 30 min. Fragmented DNA was purified using MinElute kit (QIAGEN, Cat#28206) and library was generated by PCR using NEBnext PCR mastermix (New England Biolabs (NEB), Cat#M0541). Appropriate number of PCR cycles was determined by qPCR as described (Buenrostro et al., 2015) . Libraries were sequenced on HiSeq 4000 with paired-end reads. Reads were mapped using Bowtie2 (Langmead and Salzberg, 2012) followed by removing PCR duplicates using Picard. Peaks were called using MACS2 (Zhang et al., 2008) . Peaks from two biological replicates were merged using Samtools (Li et al., 2009) and Bedtools (Quinlan and Hall, 2010 ) and subjected to DESeq2 or calculating differences between non-targeting sgRNA or sgRNA targeting PVT1.
Chromatin Immunoprecipitation (ChIP) ChIP was performed as described (Ram et al., 2011) with minor modification. Briefly, an appropriate number of MDA-MB-231 cells [2 3 10 6 cells for H3K27Ac (Abcam, Cat#ab4729) or H3K9me3 (Abcam, Cat#ab8898), 5 3 10 6 cells for Pol II-S5P (Abcam, Cat#ab5131), 1 3 10 7 cells for BRD4 (Bethyl Laboratories, Cat#A301-985A100), 2 3 10 7 cells for HA [(Cell Signaling, Cat#2367S) or Pol II-S2P (Abcam, Cat#ab5095)] or mNPC [5 3 10 6 cells for H3K9me3 or H3K4me3 (Active Motif, Cat#39159)] was harvested and crosslinked with 1% formaldehyde (Thermo Fisher, Cat#28908) for 10 min and subsequently quenched with final 0.125 M glycine. Chromatin was sheared using Covaris ultra sonicator to around 200 bp followed by centrifugation for clearing. Soluble fraction of sheared chromatin was diluted 5-fold with ChIP-dilution buffer (16.7 mM Tris pH 7.5, 127 mM NaCl, 1.2 mM EDTA, 1.1% Triton X-100 and 0.01% SDS) incubated with pre-mixed Dynabead of A-protein and G-protein (Thermo Fisher, #10002D or #10004D) without antibody at 4 C for 1 hr. After removing the bead, an appropriate antibody or negative control IgG was added to chromatin and incubated for overnight at 4 C. Antibody-bound chromatins were captured by incubating 2 hr with pre-mixed Dynabead of A-protein and G-protein. Chromatin-captured bead was washed twice with low-salt RIPA (50 mM Tris pH 8.0, 1 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.1% SDS and 0.1% DOC), twice with high-salt RIPA (50 mM Tris pH 8.0, 1 mM EDTA, 500 mM NaCl, 1% Triton X-100, 0.1% SDS and 0.1% DOC), twice with LiCl wash buffer (50 mM Tris pH 8.0 250 mM LiCl, 0.5% NP-40 and 0.5% DOC) and twice with TE (10 mM Tris pH 8.0 and 1 mM EDTA). Bead was resuspended in elution buffer (10 mM Tris pH 8.0, 5 mM EDTA, 300 mM NaCl and 0.5% SDS) and bead was removed by magnet. Proteinase K (NEB, Cat#P8107) was added to eluted DNA and incubated at 55 C for 2 hr followed by incubating at 65 C overnight and at 37 C for 30 min with RNaseA (Thermo Fisher, Cat#12091). Reverse-crosslinked DNA was purified by using MinElute column. Eluted DNA was used to qPCR or sequencing library preparation with NEBnext ultra-II kit (for human cell line, NEB, Cat#E7645) or tagmentation using Nextera enzyme (for mouse cell line). qPCR was performed using qPCR master mix (Roche, #04707516001). Each Ct value was measured using Lightcycler 480 (Roche) and each mean dCt was averaged from triplicate qPCR reaction. Ct values were normalized to relative amount of 2 to 5% of input DNA and the mean dCt value from each replicate was used for calculating p value. qPCR primers are listed in Table S1 . Sequencing libraries were sequenced on HiSeq 4000 with paired-end reads. Reads were mapped by using Bowtie2 followed by removing PCR duplicates using Picard. Peaks were called using MACS2 with subtraction of input signal. Peaks from two biological replicates were merged using Samtools and Bedtools. Differences between non-targeting sgRNA or sgRNA targeting PVT1 were analyzed by DESeq2. Enrichment of any IgG control between CRISPRi-Control and CRISPRi-PVT1 is not significantly different (p > 0.05).
JQ1 treatment 4 3 10 6 cells were plated on 6-well plate. JQ1 (Sigma Aldrich, Cat#SML1524) in DMSO was added final 1 mM or 5 mM 1 day post plating. After 6 hr, cells were harvested and RNA was extracted as decribed in qRT-PCR method. Equal volume of DMSO without JQ1 was added as a negative control.
Hi-ChIP
Hi-ChIP was performed as described (Mumbach et al., 2016) . Briefly, 1 3 10 7 cells for each biological replicate were collected and crosslinked by using 1% formaldehyde for 10 min. Chromatin was digested using MboI restriction enzyme (NEB, Cat#R0147) followed by end-repair, ligation, and sonication. Sheared chromatin was cleared and 3-fold diluted as described in ChIP method and then incubated with anti-H3K27ac antibody at 4 C for overnight. Chromatin-antibody complex was captured by Dynabead Protein-A bead. Biotin was incorporated by adding DIBO-biotin (Thermo Fisher, Cat#C-10412) followed by capture with Streptavidin C-1 bead (Thermo Fisher, Cat#65002). Captured DNA was quantified using Qubit (Thermo Fisher) and an appropriate amount of Tn5 enzyme was added to captured DNA to generate sequencing library. Sequencing was performed on HiSeq 4000 with paired-end read and analyzed by using HiC-pro (Servant et al., 2015) .
UMI-4C
UMI-4C was performed as described (Schwartzman et al., 2016) with minor modification. 5 3 10 6 cells were harvested and crosslinked with 1% formaldehyde for 10 min. Pellet was resuspended in ice-cold lysis buffer (10 mM Tris pH 8.0, 10 mM NaCl, 0.2% NP-40) and incubated at 4 C for 30 min. Nuclei was pelleted and resuspended in 0.5% SDS followed by incubation at 62 C for 10 min. Chromatin was digested by MboI restriction enzyme and ligated by T4 DNA ligase (NEB, Cat#M0202) at room temperature for 4 hr. Reaction was cleared by centrifugation. Pellet was resuspended in Proteinase K buffer (10 mM Tris pH. 7.5, 100 mM NaCl, 1 mM EDTA, 0.5% SDS) and incubated 55 C for 2 hr with Proteinase K and then incubated 68 C for 2 hr. After incubating with RNaseA, DNA was purified by ethanol precipitation. DNA was resolved in 10 mM Tris pH 7.5 and sonicated by Bioruptor followed by sequential incubation with end repair mix (NEB, Cat#E6050), Klenow exo-(NEB, Cat#M0212) and CIP (NEB, Cat#M0290). Reaction was cleared by SPRI selection (2 3, Beckman Coulter, Cat#B23318). Illumina forked adaptors was added to DNA and incubated with Quick Ligase (NEB, Cat#M2200) at room temperature for 15 min. To release the non-ligated strand of the adaptor, DNA was denatured at 95 C for 2 min and then purified by SPRI (1 3 ). Denatured DNA was quantified by Qubit. 200 ng of DNA was used for library preparation by nested PCR. Sequencing was performed on MiSeq or HiSeq 4000 with paired-end reads and analyzed by using HiC-pro. The interaction frequency was measured from two biological replicates each of which comprises two technical replicates with two different primers. Mean was normalized to CRISPRi-Control for each interaction. PCR primers used in UMI-4C are listed in Table S1 .
4C-Seq
Chromosome conformation capture combined with high-throughput sequencing (4C-Seq) was performed according to described (Stadhouders et al., 2013) with modifications. 5 3 10 6 cells were fixed by adding 37% formaldehyde to a final concentration of 1% and incubating for 10 min at room temperature while tumbling, followed by addition of 1M glycine to a final concentration of 0.125M to quench. Samples were washed with cold PBS and resuspended in 5 mL ice-cold lysis buffer (10 mM Tris-HCl (pH 8.0), 10 mM NaCl, 0.2% NP-40 supplied with proteinase inhibitor), followed by 10 min incubation on ice. Samples were re-resuspended in 500 mL 1.2 3 CutSmart restriction digest buffer (NEB). 20% SDS was added to a final concentration of 0.3%, and samples were incubated for 1 hr at 37 C while shaking at 900 rpm on a thermomixer. 20% Triton X-100 was added to a final concentration of 2%, followed by incubation for 1 hr at 37
C while shaking at 900 rpm on a thermomixer. NlaIII (NEB, #R0125) was added to each sample and incubated 20 hr at 37
C while shaking at 900 rpm on a thermomixer. To inactivate enzyme, 20% SDS was added to a final concentration of 1.6% SDS, followed by incubation for 25 min at 65
C while shaking at 900 rpm on a thermomixer. T4 DNA Ligase buffer (NEB) and T4 DNA Ligase (NEB) were added, and incubated for 18 hr at 16 C. Proteinase K (Machery Nagel, #740506) and incubating for 16 hr at 65 C. RNase was added and incubated for 30 min at 37 C. DNA was purified by phenol:chloroform extraction followed by ethanol precipitation. The second 4C-Seq digest was then performed by digestion using DpnII (NEB, #R0543) for 16 hr at 37 C. Digests were then purified using phenol:chloroform and resuspended in distillated water. Second ligation was performed by adding 10 3 T4 DNA Ligase buffer (NEB) and T4 DNA Ligase (NEB), followed by incubation for 18 hr at 16 C. Circularized fragments were purified by phenol:chloroform and resuspended in 10 mM Tris-HCl (pH 7.5), and then purified again using NucleoSpin PCR Clean-up (Machery Nagel, #740609). 1.2 mg of each template was amplified using the Expand Long Template PCR kit (Roche, #11681834001) for 30 cycles. PCR primers used for 4C-seq were described in Table S1 . PCR amplicons were purified using Agencourt Ampure XP beads. Sequencing libraries were generated using the KAPA HyperPlus kit according to manufacturer's recommendations with modifications. 4C-Seq libraries were validated using the Agilent 2200 High Sensitivity DNA ScreenTape, Qubit, and ddPCR (BioRad). Cluster generation and sequencing was performed on a HiSeq 4000 with single end read. Reads were aligned to the human genome using the spliced read aligner HISAT2 (Kim et al., 2015) .
Luciferase reporter assay
Genomic region harboring PVT1 intragenic enhancers was amplified by nested-PCR and cloned into pGL4.23[luc2/minP] vector (Promega, Cat#E8411) digeted by XhoI and HindIII using NEBuilder Hifi DNA Assembly Master Mix (NEB, Cat#E2621L). Luciferase activity was measured using Luciferase Assay System (Promega, Cat#E1500). One day prior to transfection, 1 3 10 5 of MDA-MB-231 cells plated in 24-well plate. 500 ng of plasmid was transfected into the cells using Lipofectamine 3000. Fresh media was replaced at post 24 hr transfection. At post 48 hr transfection, media was removed and the plate washed by PBS briefly. 200 ml of 1 3 Cell Culture Lysis Reagent was added to plates directly and transferred to new tubes. After brief centrifugation, 20 ml of cell lysate was mixed with 100 ml of Luciferase Assay Reagent. Luminescence was measured using pre-set protocol of SpectraMax M5 and SoftMax Pro 6.3 software (Molecular Devices).
CRISPRi targeting enhancers
In order to target enhancer region efficiently which long around 1 kb, we used three sgRNA in one vector system (Adamson et al., 2016) . In order to select cells infected both sgRNA targeting PVT1 and enhancer, lentiviral vector backbone was modified by replacing Puromycin-mCherry cassette to Hygromycin resistance gene. Three sgRNAs were designed for each enhancer and cloned into pMJ114 (bovine U6, Addgene, Cat#85995), pMJ117 (human U6, Addgene, Cat#85997) or pMJ179 (mouse U6, Addgene, Cat#85996) individually. Then, U6 promoter and sgRNA sequences were amplified by PCR and combined into lentiviral vector using NEBuilder Hifi DNA Assembly Master Mix, which digested with XbaI and XhoI. Cells infected lentivirus containing sgRNA targeting PVT1 or LacZ (control) first followed by Puromycin selection for 4 days as described above. Then, cells were re-plated by 1:8 ratio to 6 well plate and infected with lentivirus harboring three sgRNAs targeting each enhancer and selected with Hygromycin for 8 days.
After one day recovery without antibiotics, RNAs were extracted and used for qRT-PCR. Sequences of sgRNAs and primers are listed in Table S1 .
4sU-labeling Nascent RNA labeling with 4sU was performed as described with minor modification (Duffy et al., 2015) . 1 3 10 6 cells were plated on 15 cm plate 1 day prior to labeling. 4-thiouridine (Sigma Aldrich, Cat#T4509) dissolved in DMSO or equal volume of DMSO was added to media at final 200 mM and incubated at 37 C for 20 min. After incubation, cells were harvested and stored at À80 C for overnight. Total RNA was purified by adding TRIzol (Thermo Fisher, Cat#15596018) and 0.2 volume of chloroform. 1 volume of ethanol was added to aqueous phase and then transferred to RNeasy midi column (QIAGEN, Cat#75144) . RNA was eluted in RNase free water and quantified by Nanodrop. 5 mg of MTSEA biotin-XX (Biotium, Cat#90066) was added to 20 mg of RNA and then incubated for 2 hr in final 400 mL of binding buffer (10 mM HEPES pH 7.5, 1 mM EDTA and 20% dimethylformamide). After biotinylation, free biotin was washed out by purifying with RNeasy MinElute column (QIAGEN, Cat#74204). 100 mL of Streptavidin C-1 bead was added to RNA and then incubated with rotating for 1 hr in binding buffer (10 mM Tris pH 7.5, 1 mM EDTA, 100 mM NaCl and 0.1% tween-20). Bead was washed 3 times with binding buffer. RNA was eluted sequentially by 5% of b-mercaptoethanol at room temperature and 100% of b-mercaptoethanol at 50 C followed by purification using RNeasy MinElute column. Purified RNA was used to qRT-PCR for quantification and normalized to relative abundance of ACTB RNA in 5% of input RNA which was measured by qRT-PCR. Relative abundance of nascent transcripts was calculated by ddCt method compared to non-targeting sgRNA control. Mean dCt value of each replicate was used to calculate p value. Enrichment of any biotinylated-control GAPDH mRNA is not significantly different (p > 0.05). Primer sequences are listed in Table S1 .
PVT1 promoter mutagenesis
For footprinting of regulatory element affecting cell growth (Vierstra et al., 2015) , Cas9 endonuclease and sgRNA were delivered in ribonucleotide to avoid accumulation of indels by residual nuclease activity. pET28-Cas9 plasmid was transduced into BL21-DE3 (pLysS) strain (Thermo Fisher, Cat#C6060) and Cas9 protein and sgRNA were prepared and transduced as described (Cho et al., 2014) . Pre-assembled CRISPR-ribonucleoprotein complex consisting of 100 mg of Cas9 and 100 mg of sgRNA was transfected into 1 3 10 6 of MDA-MB-231 cells by using Amaxa Nucleofetor kit V (Lonza, Cat#VVCA-1003) with program X-013. Cells were plated on 6-well plate 3 days post-transfection (P0). Cells were passaged by 1:4 ratio every 2 days. At P10, genomic DNA was purified and 5 mg of DNA was used for PCR amplification of PVT1 promoter region. Parallel PCR reactions were mixed and purified using AMPure beads (Beckman Coulter, #A63881) at concentrations ranging from 0.6 3 to 1 3 . Libraries were generated by nested PCR and sequenced on HiSeq 4000 with paired-end reads. Sequencing read was analyzed using CRISPresso (Pinello et al., 2016) . Any variation without overlap with expected cleavage site ± 3 bp was ignored. Difference between P0 and P10 was calculated by DESeq2. To generate mutant clones, cells were diluted and plated as 0.2 cells in 96-well plate 2 days post ribonucleoprotein transfection. Genomic DNA was extracted using DNeasy 96 Blood & Tissue Kit (QIAGEN, Cat#69581) and 5 to 20 mL of eluted DNA was used to PCR. Target regions were amplified from each clone and sequenced with MiSeq for genotyping. Reads from each clones were counted using Fastax-collapser. For qRT-PCR, RNA was extracted from clones at multiple passages. Primer sequences are listed in Table S1 .
Targeted RNA-seq 50 ng of RNA extracted from each mNPC clone was converted to cDNA by 30 cycles of qRT-PCR reaction. Then, the region with defined SNP was amplified using 1 mL of diluted PCR product (1/20) and 15 cycles of PCR. Sequencing library was generated by 15 cycles of nested PCR using 1 mL of diluted PCR product (1/20). DNA was extracted from 1% agarose gel and sequenced on MiSeq. Reads were counted using Fastax-collapser. Reads with exactly expected sequences were considered for calculating d-score. The transcription level of each allele was averaged from 3 technical replicates. Primer sequences are listed in Table S1 .
Allelic specific data analysis All the sequencing data from mouse cell line were processed as described (Xu et al., 2017a) . The d-score for PVT1 expression was calculated using the first exon instead of the whole transcripts to better present the allelic different isoform of PVT1. The relative fold change of MYC was normalized to the average expression from clones with two active alleles of PVT1.
Deleterious score for PVT1 promoter regions To evaluate whether variants in the PVT1 promoter region were potentially deleterious in the human genome, we employed the UCSC Table Browser and specified ''Variation'' group, ''1000G ph3 Vars'' track and a 5 kb window around PVT1 transcription start sites (chr8: 128,801,802-128,811,802 ) to obtain VCF files for all variants. VCF files were analyzed using CADD (Kircher et al., 2014) (http://cadd.gs.washington.edu/score) to generate a C-score corresponding to the predicted deleteriousness of genomewide variants. The CADD C-score was used to illustrate the predicted deleterious effect for each variant, which is PHRED-like (À10 3 log10(rank/total)) scaled, ranking a variant relative to all possible substitutions of the human genome (8.6 3 10 9 ). On this scale, variants with a C-score of greater than or equal to 10 are predicted to be among the top 10% most deleterious substitutions in the human genome.
Somatic mutations around PVT1 promoter regions Somatic mutations (SNVs) for different cancer types were obtained from the International Cancer Genome Consortium (ICGC) (Release 23). Mutations within a 5 kb window of the TSS from a set of annotated lncRNAs (ENSEMBL, release 70) were evaluated where lncRNA promoter regions from Chr 1 or Chr 8 were employed as controls. The number of somatic mutations within each lncRNA promoter region for each cancer type was used to generate a background (control) distribution against which the frequency of PVT1 promoter mutations was evaluated.
Significance of SV overlaps in PVT1 promoter region Somatic structural variant (SV) calls for the ICGC BRCA-EU cohort were obtained from the original publication (Glodzik et al., 2017) . The number of SVs (less than 1 million base pair in length, for duplications, deletions or inversions) overlapping with 3,826 lncRNA promoters (ENSEMBL, release 70, with gene length > 5000 bp) was calculated. Promoters were defined as [-1000, 2414] bp of the corresponding transcription start site (TSS), keeping with the definition used in this study for PVT1. Local background SV overlap rates were computed based on the mean overlap for windows in adjacent regions (5 million bp). Negative binomial regression was performed using the local background rate as the offset and SV overlap in each promoter as the observed variable (Nik-Zainal et al., 2016) . The estimated over dispersion parameter was then used as input to a negative binomial test to evaluate the significance of SV overlap in each promoter. FDR adjusted p values were employed to correct for multiple testing.
Rearrangement analysis
Fusion transcripts and their exact breakpoints were identified in RNA-seq data (Illumina, 30 3 ) of an ER-, HER2+ breast cancer using breakpoint assembly for candidate sites with an enrichment of chimeric reads or clusters of abnormal read pairs that map to unexpectedly distant sites (Fernandez-Cuesta et al., 2015) . DNA-level breakpoints associated with the fusion events were determined based on abnormal read pairs in the vicinity of the detected fusion points by analyzing whole genome sequencing (WGS) data (30 3 ) from the same donor. The RNA-seq and WGS data for this case were generated on the Illumina platform using standard protocols. The patient (MB-0152) derives from the METABRIC cohort (Curtis et al., 2012) for which array based copy number and gene expression data were previously described.
QUANTIFICATION AND STATISTICAL ANALYSIS
In relevant figures, figure legends denote the statistical details of experiments including statistical tests used, kind of replicates and the value of n. Asterisks define degree of significance as described in the figure legends. All Student's t test and Mann-Whitney U-test were analyzed in two-sided. All the sequencing data were aligned to human genome (GRCh37/hg19) or mouse genome (NCBI37/mm9) unless indicated specifically. All statistical analyses and graphics were performed using the R Statistical Programming Language and Bioconductor (Gentleman et al., 2004) .
DATA AND SOFTWARE AVAILABILITY
All software used in this study is listed in the Key Recourses Table. ChromHMM was imported from Breast vHMEC from Roadmap Epigenomics Consortium. Conservation plot is imported from 100 vertebrates Basewise Conservation by PhyloP at UCSC genome browser. All raw sequencing reads and raw count matrices generated in this study are available through Gene Expression Omnibus (GEO) with accession number GEO: GSE97669. Data for human cancer patient is available through European Genome-Phenome Archive (EGA) with accession number EGA: EGAD00001003342.
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